<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4868">
  <stage>Registered</stage>
  <submitdate>8/04/2014</submitdate>
  <approvaldate>8/04/2014</approvaldate>
  <nctid>NCT02110355</nctid>
  <trial_identification>
    <studytitle>A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma</studytitle>
    <scientifictitle>A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>20120238</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Malignancy</healthcondition>
    <healthcondition>Advanced Solid Tumors</healthcondition>
    <healthcondition>Cancer</healthcondition>
    <healthcondition>Oncology</healthcondition>
    <healthcondition>Oncology Patients</healthcondition>
    <healthcondition>Tumors</healthcondition>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 232
Treatment: drugs - Trametinib
Treatment: drugs - Dabrafenib

Experimental: AMG 232 with Trametinib and Dabrabenib - Arm 1 of Part 1 and 2 and Part 3

Experimental: AMG 232 with Trametinib - Arm 2 of Part 1 and 2

Active Comparator: Trametinib and Dabrafenib - Part 3


Treatment: drugs: AMG 232
Given as an oral tablet in escalating doses

Treatment: drugs: Trametinib
Trametinib is an anti-cancer agent

Treatment: drugs: Dabrafenib
Dabrafenib is an anti-cancer agent

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate - Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival - Objective Tumor Response</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must have histologically or cytologically confirmed metastatic
        cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication,
        Adequate hematological, renal, hepatic, and coagulation laboratory assessments</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion
        Criteria: Clinically significant bleeding within 4 weeks of screening, Current use of
        warfarin, factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring
        anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major
        surgery within 28 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>19/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>138</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>17/08/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Research Site - North Sydney</hospital>
    <hospital>Research Site - East Melbourne</hospital>
    <postcode>2060 - North Sydney</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>GlaxoSmithKline</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in
      combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a
      direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib
      combined with dabrafenib alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02110355</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>